News | Computer-Aided Detection Software | June 01, 2018

FDA Proposes to Reclassify Some Types of Radiology Image Software Analyzers

Proposed order would reduce regulatory approval burden for various computer-aided detection devices

FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers

June 1, 2018 — The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical image analyzers, or computer-aided detection (CAD) devices, from class III to class II devices. This includes CAD devices for mammography breast cancer, ultrasound breast lesions and radiograph lung nodules.

If finalized, this proposed order will reclassify CAD devices for certain radiological applications from Class III devices requiring premarket approval, to Class II devices, requiring a less burdensome premarket notification (510(k)) with special controls. This will reduce the regulatory burden on the medical device industry, streamline review for these types of devices, and provide more timely access to these devices for patients.

The agency is proposing special controls that, in addition to general controls, will provide a reasonable assurance of safety and effectiveness.

This proposed order is part of the Center for Devices and Radiological Health’s goal to strike the right balance between premarket and postmarket data collection. This proposed order also promotes innovation in diagnostic imaging, according to the FDA, through a more consistent and streamlined approach to review many types of radiological computer aided-detection, diagnosis and triage software under the 510(k) pathway. Streamlined premarket review will provide for more timely access to these types of devices for patients, while still maintaining the highest standards of safety and effectiveness.

The agency said it welcomes comments regarding this proposed order. The comment period will be open for 60 days.

Questions about this proposed order can be directed to CDRH’s Division of Industry and Consumer Education (DICE) at [email protected], or via phone at 1-800-638-2041, or (301) 796-7100.

For more information: www.fda.gov

Related Content

This data represents wave 2 of a QuickPoLL survey conducted in partnership with an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business

Getty Images

Feature | Coronavirus (COVID-19) | July 01, 2020 | By Melinda Taschetta-Millane
Sponsored Content | Videos | PACS | June 29, 2020
Kevin Borden, Vice President of Product, Healthcare IT for Konica Minolta, talks about Improving Access and Aiding Wo
Universal digital operating system for surgery enables health tech companies and start-ups to accelerate, scale and grow

Stefan Vilsmeier, President and CEO of Brainlab Photo courtesy of Brainlab

News | Artificial Intelligence | June 26, 2020
June 26, 2020 — ...
n support of Mayo Clinic’s digital health and practice transformation initiatives, the Mayo Clinic Department of Laboratory Medicine and Pathology has initiated an enterprise-wide digital pathology implementation of the Sectra digital slide review and image storage and management system to enable digital pathology. 
News | Enterprise Imaging | June 26, 2020
June 26, 2020 —  In support of Mayo Clinic’s digital health
Visage announces cloud implementation, Visage 7 Workflow and semantic annotations
News | Enterprise Imaging | June 26, 2020
June 26, 2020 — Visage Imaging, Inc.
The American College of Radiology (ACR) Center for Research and Innovation (CRI) is pleased to announce the development of the COVID-19 Imaging Research Registry (CIRR), an effort by the ACR CRI and the ACR Data Science Institute in collaboration with the ACR and the Society of Thoracic Radiology (STR). Sharyn Katz, M.D., director of research for thoracic radiology at the University of Pennsylvania, chairs the effort’s multiple-disciplinary steering committee, which includes representation from across the i

Getty Images

News | Coronavirus (COVID-19) | June 25, 2020
June 25, 2020 — The American College of Radiology (ACR) Center for R
he FDA launched the first “FDA Insight” podcast, featuring FDA Commissioner Stephen Hahn, M.D., and FDA Deputy Commissioner for Medical and Scientific Affairs Anand Shah, M.D., discussing FDA's COVID-19 efforts, including the drug development process for a COVID-19 treatment.

Getty Images

News | Coronavirus (COVID-19) | June 25, 2020
June 25, 2020 — The FDA launched the first “...